medigraphic.com
ISSN 1028-4818 (Electronic)

2021, Number 2

<< Back Next >>

Mul Med 2021; 25 (2)

Role of the endogenous cannabinoid system in the gut

Pelaez LM, Ricardo SY, La O FK, Rodríguez MTB

Language: Spanish
References: 31
Page:
PDF size: 326.70 Kb.


ABSTRACT

The endogenous cannabinoid system is a new intercellular communication system that constitutes a crucial piece in the regulation of intestinal function. A bibliographic review was carried out in order to describe how the endogenous cannabinoid system modulates intestinal function. A total of 31 bibliographic references were consulted between books, magazines, doctoral theses and articles on the internet. It was found that endocannabinoids are immunomodulatory at the intestinal level, that the endogenous cannabinoid system regulates the composition of the intestinal microbiota and this in turn determines the concentration of endocannabinoids, in addition both secretion and intestinal motility decrease by stimulation of the endogenous cannabinoid system. The cannabinoid receptors, the endocannabinoids anandamide and 2-arachidonoylglirerol, and the proteins responsible for their synthesis and degradation are widely distributed in the intestine under physiological conditions, increasing their expression in inflammatory bowel disease, which allows it to regulate intestinal function in both conditions. . The endogenous cannabinoid system has enormous therapeutic potential in inflammatory bowel disease due to its immunosuppressive, anti-inflammatory and analgesic effects.


REFERENCES

  1. Goyal, Hemanta; Singla, Umesha; Gupta, Urvashic; May, Elizabethb. Role of cannabis in digestive disorders. European Journal of Gastroenterology and Hepatology 2017; 29(2):135-143.

  2. López Cardona AP. Función del sistema cannabinoide en maduración de ovocitos, fecundación y desarrollo embrionario en mamíferos. [Tesis]. Madrid: Universidad Complutense de Madrid; 2017. [citado 15/1/2021]. Disponible en: https://eprints.ucm.es/id/eprint/44197/1/T39056.pdf

  3. Pascual Simón JR, Fernández Rodríguez BL. Breve reseña sobre la farmacología de los cannabinoides. MEDISAN 2017; 21(3): 351-62.

  4. Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry 2016; 79(7): 516-25.

  5. Serra RSV, Palomares VPR. Cannabinoids: current uses in clinical practice. Acta Med 2015; 13(4): 244-250.

  6. Alexander SP. Therapeutic potential of cannabis-related drugs. Prog Neuropsychopharmacol Biol Psychiatry 2016; 64: 157-66.

  7. Ambrose T, Simmons A. Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2019; 13(4): 525–535.

  8. Di Marzo V, Piscitelli F. The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics 2015; 12(4): 692–8.

  9. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev 2016; (5): CD005336.

  10. Cortés Romero CE, Báez Duarte BG, Zamora Ginez I, Bilbao Reboredo T, Cebada Ruiz JA, Galicia S, et al. Regulación de la ingesta de alimento: una aproximación al sistema endocannabinoide. VITAE. [Internet]. 2015 [citado 9/2/2021]; (61). Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=6460932

  11. Soria Lara DM, Gaitán Vélez BV, Jiménez Islas H, Miranda López R. El Sistema de Endocannabinoides como regulador de la lipogénesis y su posible modulación por la mangiferina. Rev Biomed 2019; 30(2): 83-102.

  12. Viader A, Blankman JL, Zhong P, Liu X, Schlosburg JE, Joslyn CM, et al. Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action. Cell Rep 2015; 12(5): 798-808.

  13. Hasenoehrl C, Taschler U, Storr M, Schicho R. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil 2016; 28(12): 1765-1780.

  14. Suárez J, Romero Zerbo Y, Márquez L, Rivera P, Iglesias M, Bermúdez Silva FJ, et al. Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids. Plos one 2012; 7(5): e37729.

  15. Fride E. El sistema cannabinoide endógeno: un nuevo componente en el eje cerebro-tracto digestivo-tejido adiposo. Cannabinoids 2007; 2(2): 5-12.

  16. Acharya N, Penukonda S, Shcheglova T, Hagymasi AT, Basu S, Srivastava PK. Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proc Natl Acad Sci USA 2017; 114(19): 5005-5010.

  17. Leinwand KL, Jones AA, Huang RH, Jedlicka P, Kao DJ, Zoeten EF, et al. Cannabinoid receptor-2 ameliorates inflammation in murine model of Crohn’s disease. J Crohns Colitis 2017; 11(11): 1369–1380.

  18. Katz D, Katz I, Porat Katz BS, Shoenfeld Y. Medical cannabis: Another piece in the mosaic of autoimmunity? Clin Pharmacol Ther 2017; 101(2): 230-238.

  19. Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: A systematic review. Autoimmun Rev 2016; 15(6): 513-528.

  20. Turcotte C, Chouinard F, Lefebvre JS, Flamand N. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J. Leukoc. Biol. 2015; 97(6): 1049-1070.

  21. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut Ch, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-37.

  22. Lee Y, Jo J, Young Chung H, Pothoulakis C, Im E. Endocannabinoids in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 2016; 311(4): G655-G666.

  23. Abhilash Perisetti, Hossain Rimu A, Ali Khan S, Bansal P, Goyal H. Role of cannabis in inflammatory bowel diseases. Ann Gastroenterol. Mar-Abr 2020; 33 (2): 133-144.

  24. Salaga M, Abalo R, Fichna J. Cannabis and Cannabinoids and the effects on gastrointestinal function: An overview. In: Preedy V. Handbook of Cannabis and Related Pathologies. Reino Unido: Academic Press; 2017. Cap 49. P. 450-480.

  25. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Luvone T, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001; 134(3): 563–570.

  26. Marín Jiménez I. Efecto del sistema cannabinoide endógeno sobre la función de barrera intestinal. [Tesis]. Madrid: Universidad Complutense de Madrid; 2019. [citado 21/1/2021]. Disponible en: https://eprints.ucm.es/id/eprint/50903/1/T40807.pdf

  27. Silvaa F, Gaticab, Pavez C. Etiología y fisiopatología de la enfermedad inflamatoria intestinal. Rev. Med. Clin. Condes. 2019; 30(4): 262-272.

  28. Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care 2017; 44(4): 673-692.

  29. Couch D, Maudslay H, Doleman B, Lund JN, Sullivan SE. The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2018; 24(4): 680– 97.

  30. Gómez M, Sierra J. El rol de la microbiota intestinal. BIOCIENCIAS, 2019(1).

  31. Pesce M, Esposito G, Sarnelli G. Endocannabinoids in the treatment of gasytrointestinal inflammation and symptoms. Curr Opin Pharmacol 2018; 43: 81-86.




2020     |     www.medigraphic.com